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Editorial 
Autologous bone graft with bone obtained from the iliac 
crest has long been used in spinal fusion surgery (1). 
Reports of morbidity associated with harvesting iliac crest 
bone graft (ICBG) have led to an ongoing quest for bone 
graft substitutes. Ever since Urist introduced the use of 
bone morphogenic protein (BMP) in 1960, BMPs have 
been the subject of debate and various research projects (2). 
BMP-2 (Infuse, Medtronics) has been FDA approved 
for anterior lumbar interbody fusion. BMP-7 [Osigraft 
(OS) and OP1 Putty, Stryker] has only been granted a 
Humanitarian exemption for revision posterolateral fusion 
in compromised patients.
Delawi et al. recently published a multicenter randomized 
trial investigating BMP-7 (OS, Stryker) vs. ICBG (3) for one 
level instrumented posterolateral fusion of the lumbar spine 
for degenerative or isthmic spondylolisthesis (grade 1 to 2). 
The strength of their study comes from the following two 
study design features: randomized trial and the use of CT 
scan to assess bone bridging. They found that the overall 
fusion rate using OS was significantly lower (54%) than 
that of ICBG (74%) and that it cannot be recommended for 
fusion in posterolateral instrumented fusion. The clinical 
outcome (Oswestry disability index, ODI), however, was 
comparable in both the groups (84% in OS group compared 
to 86% in ICBG group). The OS group had a significantly 
higher number of smokers although they did not find this 
to be of any significance through a regression analysis.
Vaccaro et al. in their study comparing OP1 Putty 
(Stryker) and ICBG for degenerative listhesis, used CT scan 
and also radiological angulation/translation criterion to 
assess fusion (angulation <5 degree and translation <3 mm 
as fusion success) (4). Using the radiological angulation/
translation criterion, they found similar fusion rates of 
69.3% vs. 68.4% for angulation and 74.8% vs. 75.7% for 
translation by 36 months. Clinical outcomes at 2 years 
using ODI were also comparable; 74.5% in the OP1 group 
vs. 75.7% in the ICBG group. The CT scan performed 
at 24 months and greater than 36 months showed varying 
results. At 2 years, bridging bone at the graft site was 
seen in 61.7% in the OP1 group compared to 83.1% in 
the ICBG group (P<0.001). At the last follow up (over 
36 months), CT showed comparable fusion rates (74.8% in 
the OP1 group compared to 77.4% in the ICBG group).
Based on the above observation, assessing bridging fusion 
by CT scan at 1 year (as was done in the Delawi study) may 
be too early since it seems that the process continues beyond 
1 year. The slightly higher fusion rates based on the CT 
scans in the study by Vaccaro et al. (61.7%) compared to the 
Delawi et al. study (54%) could be due to several reasons 
(3,4). The fusion assessment time period was different, as 
mentioned above. Only degenerative listhesis was included 
in the Vaccaro study while the Delawi study also included 
isthmic cases. What was most interesting to note was the 
type of BMP-7 used in the studies. Vaccaro et al. used OP1 
putty in their study while Delawi et al. used OS. OS is 
predominately available in Europe. OP1 Putty (which is the 
same as OS in constituent) is available in the United States 
but has an additional component, carboxymethylcellulose 
(CMC), which may be a factor in enhancing adhesion (5-7). 
Currently, there is no literature that directly compares the 
effectiveness of OS to OP1 putty (with CMC). Studies have 
shown that CMC improves bone formation. Research into 
120 Drazin et al. BMPs for select spinal surgeries merit further research
© Journal of Spine Surgery. All rights reserved. J Spine Surg 2017;3(1):119-121jss.amegroups.com
the effectiveness of OP1 and CMC should be conducted 
to further evaluate and validate its effectiveness in fusion 
procedures.
Delawi et al. included only grade 1 and 2 listhesis patients 
in their study. The results (clinical and radiological) were 
not categorized with respect to degenerative or isthmic 
type. It would have been interesting to see if the fusion 
rates and clinical outcomes differ with respect to the type of 
listhesis. This may have been a factor, especially in isthmic 
spondylolisthesis where high sheer stress at times requires 
robust circumferential fixation techniques.
Iliac crest autografts do have drawbacks with higher rates 
of complications including: nerve, arterial and urethral 
injury, pelvic fractures, gait disturbances, hematoma, 
infection and chronic pain at the harvest site, in addition to 
chronic neuralgia (8).
One potential advantage of using OS is avoidance of 
morbidity associated with harvesting ICBG, although 
Delawi et al. reported no difference in the two groups. We 
agree with the Delawi et al. suggestion that the degree of 
pain attributed to the donor site is probably over-estimated. 
Also, the technique of harvesting autograft also plays a role 
with associated morbidity (9,10).
It is important to note that Delawi et al. did not report 
any adverse events with the use of BMP-7. Although they 
reported that reoperation rates were higher in the OS 
group (ten cases compared to two), this was not associated 
with use of OS. There has been controversy in the use of 
BMP-2. Tannoury et al. explored the complications of bone 
morphogenetic proteins in depth, concluding that its use 
should be reserved for patients with no other alternative (9). 
The Yale University Open Data Access (YODA) studies, 
however, indicated the efficacy of BMP-2 to be equivalent 
or superior in achieving fusion as compared to autologous 
bone graft. BMP-2 is used most often in spine surgery as an 
off-label use.
Concerns of carcinogenesis remain at the forefront when 
discussing BMP complications, with cancer appearing at 
the top of the list of adverse effects; media coverage on 
OP1’s rare carcinogenic effects has skewed public opinion 
negatively, influencing patients’ decisions about its use (11). 
Although previous research may have indicated a 
correlation between BMP use and increased incidence for 
malignancy, its association has been highly exaggerated 
by the media. Current literature suggests no statistical 
significance between BMP treatment and cancer (12). Two 
recent studies by Dettori et al. and Malham et al., found 
no significant association between BMP and the risk of 
cancer (12,13).
New fusion techniques are constantly evolving, 
with advancements in technology, biomaterials and 
instrumentation that may lead to alternatives for  standard 
therapies. These alternatives may include off label uses of 
medications, such as the current off label use of BMPs in 
spine surgery. My personal experience has been that many 
of our patients prefer that we use OP1 instead of an iliac 
crest autograft because it eliminates the need for them to 
undergo an additional incision and procedure with possible 
complications. 
Delawi et al. did an evidence based study comparing the 
effectiveness of BMP-7 use with ICBG, the current gold 
standard. Although Delawi et al. could not prove statistical 
non-inferiority, this study does suggest areas of further 
research. BMPs show promise as a means for interbody and 
onlay fusion in spine surgery. Further research studies may 
uncover more promising data showing the benefits of BMP 
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